Expert Committee for the development of tumor immunotherapy for prostate carcinoma
The Expert Committee for the development of the medication for tumor immunotherapy of prostate carcinoma involves globally recognized experts in the field. The chief goal and focus of the Expert Committee is independent consulting with regard to SOTIO’s clinical development of immunotherapy for patients with prostate carcinoma and the evaluation of the development results. The Expert Committee members’ experience in research and clinical practice is another major building block in the process of introducing new treatment methods developed by SOTIO to clinical practice.
The Expert Committee members include Philip W. Kantoff, Professor at Harvard Medical School (US) and a globally renowned prostate carcinoma treatment expert; Michael Marberger, Professor Emeritus at the Department of Urology of the University of Vienna Medical School; Vesa V. Kataja, Professor at University of Eastern Finland and the Head Physician of Cancer Center, Kuopio University Hospital, Finland and Susan Slovin, Associate Professor of Medicine at Weill Cornell Medical College (US) and a principal investigator of the VIABLE phase III study.
Prof. Philip W. Kantoff, M.D.
Chief Clinical Research Officer, Vice Chair of Department of Medical Oncology, Solid Tumor Oncology, USA
Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, USA
Professor of Medicine, Harvard Medical School, USA
Assoc. Prof. Susan Slovin, M.D., Ph.D.
Associate Member, the Genitourinary Oncology Service at the Department of Medicine, Memorial Sloan-Kettering Cancer Center, USA
Associate Attending Physician, Memorial Hospital for Cancer & Allied Diseases, USA
Director, Chemotherapy Unit, Experimental Therapeutics Unit, Sidney Kimmel Center for Prostate and Urologic Cancers, USA
Associate Professor of Medicine, Weill Cornell Medical College, USA